PETACH TIKVA, Israel, January 8, 2018 /PRNewswire/ --
OWC Pharmaceutical Research Corp. [OWC Pharma](OTCQB: OWCP) is pleased to announce it will be a Diamond Sponsor at the 2018 Wall Street Conference. (http://WallStConference.com )
This is second consecutive year OWC Pharma will be attending this prestigious investment conference to be held on February 21st , 2018 at the Hilton Doubletree Hotel & Convention Center in Boca Raton, Florida.
The Wall Street Conference is one of the premiere conferences in the venture capital arena and Small Cap marketplace. Financial industry leaders from the hedge fund, investment banking, and private equity worlds, as well as sophisticated investors, attend the Wall Street Conference every year to discuss significant trends in emerging and growth industries.
Dr. Stanley Hirsch OWC Pharma Chairman commented, "I am delighted to be attending and presenting at the 2018 Wall Street Conference. I look forward to updating our supporters on current developments within the expanding medical cannabis industry in general and specifically within our company."
"It is an honor to have OWC Pharma participating again at the 2018 Wall Street Conference as a Diamond sponsor. They have a world class management team and are at the cutting edge of Medical Cannabis Research," said Jason Lyons, Founder and CEO of the Wall Street Conference.
About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/.
Notice Regarding Forward-Looking Statements
This Letter to Shareholders contains 'forward-looking statements' as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this Letter, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) reports filed with the Securities and Exchange Commission.
Chairman and CEO
SOURCE OWC Pharmaceutical Research Corp.